Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma

Oncology Research and Treatment

Volumn 37, Issue 12, 2014, Pages 757-760

  O'Kane, Grainne M ^a   Lyons, Tomas G ^a   Colleran, Gabrielle C ^a   Ahmad, Marzuki Wan ^a   Alken, Scheryll ^a   Kavanagh, Eoin C ^a   Fitzpatrick, David ^b   Murray, Brian ^a   Kelly, Catherine M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b ST LUKE S HOSPITAL   (Ireland)

Author keywords

Immunotherapy; Melanoma; Side effects

Indexed keywords

IPILIMUMAB; MEPREDNISONE; PREDNISONE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FLUORODEOXYGLUCOSE F18; RADIOPHARMACEUTICALS; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COLITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARAPLEGIA; POSTOPERATIVE PERIOD; SPINAL CORD DECOMPRESSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIAGNOSTIC USE; HUMANS; MAGNETIC RESONANCE IMAGING; MELANOMA; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; COLITIS; DACARBAZINE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; MULTIMODAL IMAGING; MYELITIS; PARAPLEGIA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84919828890     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000368316     Document Type: Article

References (25)

1. Lens MB, Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-185.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
4. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al.: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-114.
6. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, et al.: A randomized, double-blind, placebocontrolled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
7. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, et al.: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21: 1712-1717.
8. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, et al.: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
9. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-5956.
10. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
11. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-2289.
12. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 Pt 1):6681-6688.
13. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-1775.
14. Seregard S, Lundell G, Svedberg H, Kivelä T: Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology 2004;111:1228-1232.
15. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al.: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-931.
16. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ: A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012;5:404-407.
17. www.clinicaltrials.gov.
18. Hunter G, Voll C, Robinson CA: Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009;36:518-520.
19. Wilgenhof S, Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22:991-993.
20. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, et al.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-830.
21. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012;30:e76-e78.
22. Bhatia S, Huber BR, Upton MP, Thompson JA: Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009;32:203-205.
23. Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, Ouologuem M, Renard JL, Gorochov G, Robert C, et al.: Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs 2012;30:2407-2410.
24. Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA: Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2014, in press.
25. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589-593.